OsseoScrew Versus Fenestrated Pedicle Screws Augmented With Polymethylmethacrylate (EVOLVE)
Expandable Pedicle Screws Versus Fenestrated Pedicle Screws Augmented With Polymethylmethacrylate (PMMA): Complications and Clinical Outcomes in Patients With Osteoporosis or Poor Bone Quality
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium
- O.L. Vrouwziekenhuis
-
Bruxelles, Belgium
- ULB Hôpital Erasme
-
Bruxelles, Belgium
- CHIREC du Clinique
-
Liege, Belgium
- CHC St. Joseph
-
-
-
-
-
Koblenz, Germany
- Katholisches Klinikum Koblenz - Montabaur/
-
Mainz, Germany
- University Medical Center Mainz/
-
-
-
-
-
Rome, Italy
- San Giovanni Addolorata Hospital
-
-
-
-
-
Gerona, Spain
- Institut d'Assistència Sanitària
-
Leon, Spain
- Hospital de León
-
-
-
-
-
Stanmore, United Kingdom
- The Royal National Orthopaedic Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥ 18 years of age
- Spinal instability or deformity requiring fusion with instrumentation
- Osteopenia defined as (T-Score of less than -1.0)
- No response to nonoperative treatment modalities preceding enrollment.
- Subject is willing and able to provide informed consent and agrees to release medical information for purposes of this study and to return for scheduled follow-up evaluations
Exclusion Criteria:
- Active systemic or local infection
- A life expectancy less than the study duration
- Autoimmune disorders
- Currently an alcohol, solvent, or drug abuser
- Psychiatric or cognitive impairment that, in the opinion of the investigator, would interfere with the subject's ability to comply with the study requirements
- History of allergies to any of the device components including but not limited to commercially pure titanium, titanium alloy, polymethylmethacrylate or Zirconium Oxide (ZrO2)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
OsseoScrew
Test Product: OsseoScrew Spinal Fixation System
|
Surgical intervention
|
|
Fenestrated Screw
Control Product: Any commercially available fenestrated screw system augmented with PMMA
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety Endpoint: Rate of device-related or PMMA-related complications
Time Frame: 24 months
|
The proportion of patients who were free from device-related or PMMA-related complications leading to revision, supplemental fixation, non-elective removal, or reoperation throughout the study.
Complications included, but were not limited to device or PMMA fracture, device or PMMA-related loosening, device or PMMA-related device disassembly, device migration or PMMA extravasation.
|
24 months
|
|
Efficacy Endpoint: Successful radiographic fusion
Time Frame: 24 months
|
Presence of continuous bridging bone across the implant
|
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oswestry Disability Index
Time Frame: 24 months
|
This is a measure of the patient's self reported permanent functional disability.
Each section is scored on a 1-5 scale with 5 representing the greatest disability.
|
24 months
|
|
Visual Analogue Scale for back pain
Time Frame: 24 months
|
This is a measure of the characteristic or attitude that is believed to range across a continuum of values to measure pain intensity.
The range of score is from 0 - 100.
The patient marks on the line the point that they feel represents their perception of their current state.
A higher score indicates greater pain intensity.
|
24 months
|
|
Adverse events
Time Frame: 24 months
|
Adverse event rates
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bita Ghadimi, Alphatec Spine, Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- REC-000784
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.